Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome
diseaseOn this page
Also known as SOLAMEN syndrome
Summary
Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome (MONDO:0015293) is a disease with 1 cohort gene.
At a glance
- Cohort genes: 1
- ClinVar variants: 1
- Phenotypes (HPO): 19
Clinical features
Signs & symptoms
Clinical features (HPO)
19 HPO clinical features (Orphanet curated; top 19 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0001482 | Subcutaneous nodule | Very frequent (80-99%) |
| HP:0005293 | Venous insufficiency | Very frequent (80-99%) |
| HP:0007392 | Excessive wrinkled skin | Very frequent (80-99%) |
| HP:0100026 | Arteriovenous malformation | Very frequent (80-99%) |
| HP:0100559 | Lower limb asymmetry | Very frequent (80-99%) |
| HP:0100560 | Upper limb asymmetry | Very frequent (80-99%) |
| HP:0100761 | Visceral angiomatosis | Very frequent (80-99%) |
| HP:0100764 | Lymphangioma | Very frequent (80-99%) |
| HP:0200034 | Papule | Very frequent (80-99%) |
| HP:0004349 | Reduced bone mineral density | Frequent (30-79%) |
| HP:0010566 | Hamartoma | Frequent (30-79%) |
| HP:0000256 | Macrocephaly | Occasional (5-29%) |
| HP:0001635 | Congestive heart failure | Occasional (5-29%) |
| HP:0001883 | Talipes | Occasional (5-29%) |
| HP:0002757 | Recurrent fractures | Occasional (5-29%) |
| HP:0004374 | Hemiplegia/hemiparesis | Occasional (5-29%) |
| HP:0100013 | Neoplasm of the breast | Occasional (5-29%) |
| HP:0100031 | Neoplasm of the thyroid gland | Occasional (5-29%) |
| HP:0100615 | Ovarian neoplasm | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome |
| Mondo ID | MONDO:0015293 |
| Orphanet | 137608 |
| SNOMED CT | 763867001 |
| UMLS | C4706610 |
| MedGen | 1637405 |
| GARD | 0019881 |
| Is cancer (heuristic) | no |
Also known as: SOLAMEN syndrome
Data availability: 1 ClinVar variant.
Disease family
Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system benign neoplasm › benign neoplasm of skin › melanocytic nevus › segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome
Related subtypes (27): conjunctival nevus, blue nevus, halo nevus, intradermal nevus, pigmented spindle cell nevus, nevus, epidermal, neurocutaneous melanocytosis, neutrophil actin dysfunction, CHILD syndrome, Becker nevus syndrome, CLOVES syndrome, nevus comedonicus syndrome, congenital panfollicular nevus, porokeratotic eccrine ostial and dermal duct nevus, hereditary mucosal leukokeratosis, linear verrucous nevus syndrome, nevus of Ota, nevus of Ito, phakomatosis pigmentokeratotica, PENS syndrome, Angora hair nevus, didymosis aplasticosebacea, scalp syndrome, Nevada syndrome, palpebral nevus, large congenital melanocytic nevus, benign melanocytic skin nevus
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
1 retrieved; paginated sample, class counts are floors:
1 pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 536549 | NM_000314.8(PTEN):c.801G>T (p.Lys267Asn) | PTEN | Pathogenic | reviewed by expert panel |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 0 · Orphanet: 14 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| PTEN | Orphanet:109 | Bannayan-Riley-Ruvalcaba syndrome |
| PTEN | Orphanet:137608 | Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome |
| PTEN | Orphanet:145 | Hereditary breast and/or ovarian cancer syndrome |
| PTEN | Orphanet:201 | Cowden syndrome |
| PTEN | Orphanet:210548 | Macrocephaly-intellectual disability-autism syndrome |
| PTEN | Orphanet:2969 | Proteus-like syndrome |
| PTEN | Orphanet:494547 | Squamous cell carcinoma of the hypopharynx |
| PTEN | Orphanet:494550 | Squamous cell carcinoma of the larynx |
| PTEN | Orphanet:500464 | Squamous cell carcinoma of the nasal cavity and paranasal sinuses |
| PTEN | Orphanet:500478 | Squamous cell carcinoma of the oropharynx |
| PTEN | Orphanet:502363 | Squamous cell carcinoma of the oral cavity |
| PTEN | Orphanet:502366 | Squamous cell carcinoma of the lip |
| PTEN | Orphanet:65285 | Lhermitte-Duclos disease |
| PTEN | Orphanet:79076 | Juvenile polyposis of infancy |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| PTEN | HGNC:9588 | ENSG00000171862 | P60484 | Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN | clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| PTEN | Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN | Dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. |
Protein-family classification
Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Phosphatase | 1 | 83.9× | 0.012 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| PTEN | Phosphatase | yes | 3.1.3.16 | Tyr_Pase_dom, Tyr_Pase_cat, Tensin_C2-dom |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| calcaneal tendon | 1 |
| endothelial cell | 1 |
| sperm | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| PTEN | 256 | ubiquitous | marker | sperm, endothelial cell, calcaneal tendon |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| PTEN | 11,626 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| PTEN | P60484 | 12 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 13. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| PTEN Loss of Function in Cancer | 1 | 5710.0× | 0.002 | PTEN |
| Regulation of PTEN mRNA translation | 1 | 1142.0× | 0.004 | PTEN |
| Regulation of PTEN localization | 1 | 1038.2× | 0.004 | PTEN |
| Synthesis of IP3 and IP4 in the cytosol | 1 | 423.0× | 0.007 | PTEN |
| Transcriptional Regulation by MECP2 | 1 | 317.2× | 0.007 | PTEN |
| Negative regulation of the PI3K/AKT network | 1 | 278.5× | 0.007 | PTEN |
| Ovarian tumor domain proteases | 1 | 278.5× | 0.007 | PTEN |
| Synthesis of PIPs at the plasma membrane | 1 | 211.5× | 0.007 | PTEN |
| Regulation of PTEN stability and activity | 1 | 184.2× | 0.007 | PTEN |
| Regulation of PTEN gene transcription | 1 | 178.4× | 0.007 | PTEN |
| TP53 Regulates Metabolic Genes | 1 | 129.8× | 0.008 | PTEN |
| Downstream TCR signaling | 1 | 128.3× | 0.008 | PTEN |
| Ub-specific processing proteases | 1 | 53.1× | 0.019 | PTEN |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| negative regulation of synaptic vesicle clustering | 1 | 8426.0× | 0.002 | PTEN |
| negative regulation of keratinocyte migration | 1 | 5617.3× | 0.002 | PTEN |
| rhythmic synaptic transmission | 1 | 4213.0× | 0.002 | PTEN |
| central nervous system myelin maintenance | 1 | 2808.7× | 0.002 | PTEN |
| negative regulation of cell cycle G1/S phase transition | 1 | 2407.4× | 0.002 | PTEN |
| negative regulation of wound healing, spreading of epidermal cells | 1 | 2407.4× | 0.002 | PTEN |
| spindle assembly involved in female meiosis | 1 | 1872.4× | 0.002 | PTEN |
| central nervous system neuron axonogenesis | 1 | 1872.4× | 0.002 | PTEN |
| postsynaptic density assembly | 1 | 1872.4× | 0.002 | PTEN |
| neuron-neuron synaptic transmission | 1 | 1685.2× | 0.002 | PTEN |
| negative regulation of peptidyl-serine phosphorylation | 1 | 1685.2× | 0.002 | PTEN |
| negative regulation of cell size | 1 | 1685.2× | 0.002 | PTEN |
| presynaptic membrane assembly | 1 | 1685.2× | 0.002 | PTEN |
| negative regulation of organ growth | 1 | 1404.3× | 0.002 | PTEN |
| forebrain morphogenesis | 1 | 1404.3× | 0.002 | PTEN |
| multicellular organismal response to stress | 1 | 1296.3× | 0.002 | PTEN |
| negative regulation of axonogenesis | 1 | 1296.3× | 0.002 | PTEN |
| cellular response to electrical stimulus | 1 | 1296.3× | 0.002 | PTEN |
| negative regulation of excitatory postsynaptic potential | 1 | 1296.3× | 0.002 | PTEN |
| maternal behavior | 1 | 1123.5× | 0.002 | PTEN |
| prepulse inhibition | 1 | 1123.5× | 0.002 | PTEN |
| locomotor rhythm | 1 | 1053.2× | 0.003 | PTEN |
| synapse maturation | 1 | 936.2× | 0.003 | PTEN |
| dendritic spine morphogenesis | 1 | 887.0× | 0.003 | PTEN |
| negative regulation of focal adhesion assembly | 1 | 766.0× | 0.003 | PTEN |
| regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction | 1 | 702.2× | 0.003 | PTEN |
| negative regulation of vascular associated smooth muscle cell proliferation | 1 | 674.1× | 0.003 | PTEN |
| phosphatidylinositol dephosphorylation | 1 | 648.1× | 0.003 | PTEN |
| positive regulation of intracellular signal transduction | 1 | 648.1× | 0.003 | PTEN |
| negative regulation of cellular senescence | 1 | 648.1× | 0.003 | PTEN |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1
Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| PTEN | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 1.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| PTEN | 8 | Binding:8 |
Cohort enzymes (BRENDA EC)
| Symbol | EC numbers | Names |
|---|---|---|
| PTEN | 3.1.3.16, 3.1.3.67 | protein-serine/threonine phosphatase, phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase |
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 1 | PTEN |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 0 |
Undrugged target profiles
1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| PTEN | 8 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: PTEN